New study of 3 million patients with diabetes found that the use of semaglutide (Ozempic) is linked with a more than 4 times greater risk of nonarteritic anterior ischemic optic neuropathy (NAION) compared with non-GLP-1RAs (empagliflozin, sitagliptin, and glipizide).
